Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma.

ABSTRACT:

Introduction

Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, and the main treatment for UM is currently surgery and plaque brachytherapy. UM is highly susceptible to metastasis, which eventually occurs in nearly half of all patients; once metastasis occurs, patients have a poor prognosis and the condition is difficult to treat. Therefore, the identification of new and effective UM biomarkers is vital for the application of therapeutic strategies. Immunogenic cell death (ICD) is a type of regulatory cell death that activates adaptive immune responses and generates long-term immunological memory. ICD can promote antitumor immunity, which may be a potential immunotherapeutic strategy for UM.

Methods

The data of UM from the Cancer Genome Atl

SUBMITTER: Hu Y 

PROVIDER: S-EPMC9709208 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature